Published in Virol J on October 24, 2011
Lassa fever in post-conflict sierra leone. PLoS Negl Trop Dis (2014) 2.23
Undiagnosed acute viral febrile illnesses, Sierra Leone. Emerg Infect Dis (2014) 1.72
Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC). PLoS One (2015) 1.43
Enhanced methods for unbiased deep sequencing of Lassa and Ebola RNA viruses from clinical and biological samples. Genome Biol (2014) 1.16
Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. Viral Immunol (2015) 1.09
Discovery of novel rhabdoviruses in the blood of healthy individuals from West Africa. PLoS Negl Trop Dis (2015) 0.91
Advanced vaccine candidates for Lassa fever. Viruses (2012) 0.90
The search for animal models for Lassa fever vaccine development. Expert Rev Vaccines (2013) 0.84
Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali. Emerg Infect Dis (2016) 0.81
Development of Prototype Filovirus Recombinant Antigen Immunoassays. J Infect Dis (2015) 0.79
Lassa Fever in Pregnancy: Report of 2 Cases Seen at the University College Hospital, Ibadan. Case Rep Obstet Gynecol (2016) 0.76
Factors associated with mortality in febrile patients in a government referral hospital in the Kenema district of Sierra Leone. Am J Trop Med Hyg (2014) 0.75
Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man. Future Virol (2015) 0.75
Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers. PLoS Negl Trop Dis (2017) 0.75
Lassa fever. Effective therapy with ribavirin. N Engl J Med (1986) 6.38
A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis (1987) 5.27
Different B cell populations mediate early and late memory during an endogenous immune response. Science (2011) 3.63
A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis (1987) 3.51
Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ (1995) 3.21
Clinical virology of Lassa fever in hospitalized patients. J Infect Dis (1987) 2.94
Imported lassa fever in Germany: molecular characterization of a new lassa virus strain. Emerg Infect Dis (2000) 2.69
High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations. Blood (2010) 2.37
Risk maps of Lassa fever in West Africa. PLoS Negl Trop Dis (2009) 2.33
Human IgM+CD27+ B cells: memory B cells or "memory" B cells? J Immunol (2007) 2.26
Imported Lassa fever in Germany: surveillance and management of contact persons. Clin Infect Dis (2003) 1.91
Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect (2002) 1.71
Effect of environmental factors on aerosol-induced Lassa virus infection. J Med Virol (1984) 1.47
Improved detection of Lassa virus by reverse transcription-PCR targeting the 5' region of S RNA. J Clin Microbiol (2010) 1.45
Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J Infect Dis (2001) 1.40
Epidemiology and control of Lassa fever. Curr Top Microbiol Immunol (1987) 1.40
Impaired antibody response causes persistence of prototypic T cell-contained virus. PLoS Biol (2009) 1.31
Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report. Virol J (2011) 1.29
Clinical, epidemiologic, and therapeutic aspects of Lassa fever. Med Microbiol Immunol (1986) 1.22
Pathogenesis of Lassa fever in cynomolgus macaques. Virol J (2011) 1.16
Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case report. Virol J (2011) 1.13
T cell leukemia/lymphoma 1 and galectin-1 regulate survival/cell death pathways in human naive and IgM+ memory B cells through altering balances in Bcl-2 family proteins. J Immunol (2009) 1.06
Lassa fever is unheralded problem in West Africa. Nat Med (2001) 0.92
Development of immunoglobulin M memory to both a T-cell-independent and a T-cell-dependent antigen following infection with Vibrio cholerae O1 in Bangladesh. Infect Immun (2009) 0.91
Parameters governing exhaustion of rare T cell-independent neutralizing IgM-producing B cells after LCMV infection. Eur J Immunol (2006) 0.87
Persistent anti-gag, -Nef, and -Rev IgM levels as markers of the impaired functions of CD4+ T-helper lymphocytes during SIVmac251 infection of cynomolgus macaques. J Acquir Immune Defic Syndr (2005) 0.82
Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med (2014) 5.17
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg (2010) 2.92
New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res (2007) 2.47
Undiagnosed acute viral febrile illnesses, Sierra Leone. Emerg Infect Dis (2014) 1.72
Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J (2005) 1.41
Proteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes). Theor Biol Med Model (2004) 1.41
Detection of Lassa virus, Mali. Emerg Infect Dis (2010) 1.41
Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report. Virol J (2011) 1.29
Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology (2004) 1.22
Enhanced methods for unbiased deep sequencing of Lassa and Ebola RNA viruses from clinical and biological samples. Genome Biol (2014) 1.16
Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein. J Virol (2005) 1.16
Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case report. Virol J (2011) 1.13
Hierarchical modeling and other spatial analyses in prostate cancer incidence data. Am J Prev Med (2006) 1.12
Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance. Virol J (2008) 1.10
Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. Viral Immunol (2015) 1.09
Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. Virol J (2010) 1.08
Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice. Neuromolecular Med (2007) 1.06
Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma. Virol J (2005) 1.04
Ribavirin for Lassa fever postexposure prophylaxis. Emerg Infect Dis (2010) 0.99
The aromatic domain of the coronavirus class I viral fusion protein induces membrane permeabilization: putative role during viral entry. Biochemistry (2005) 0.99
Release of dengue virus genome induced by a peptide inhibitor. PLoS One (2012) 0.97
Role of endogenous retroviruses in autoimmune diseases. Infect Dis Clin North Am (2006) 0.97
Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone. Am J Pathol (2004) 0.95
The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. Virology (2010) 0.94
Viroporin potential of the lentivirus lytic peptide (LLP) domains of the HIV-1 gp41 protein. Virol J (2007) 0.94
Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon. Virol J (2007) 0.93
Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: implications for GP1 ectodomain shedding. Virol J (2008) 0.93
Mechanism of HCV's resistance to IFN-α in cell culture involves expression of functional IFN-α receptor 1. Virol J (2011) 0.93
Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol J (2010) 0.92
Alpha interferon inhibits translation mediated by the internal ribosome entry site of six different hepatitis C virus genotypes. J Gen Virol (2005) 0.91
Preventing neonatal HIV: a review. Curr HIV Res (2003) 0.90
Human, rhesus macaque, and feline sequences highly similar to mouse mammary tumor virus sequences. Microsc Res Tech (2005) 0.90
Of mice, cats, and men: is human breast cancer a zoonosis? Microsc Res Tech (2005) 0.90
Small interfering RNA targeted to stem-loop II of the 5' untranslated region effectively inhibits expression of six HCV genotypes. Virol J (2006) 0.89
Antibodies to squalene in recipients of anthrax vaccine. Exp Mol Pathol (2002) 0.89
Proteomics computational analyses suggest that baculovirus GP64 superfamily proteins are class III penetrenes. Virol J (2008) 0.88
Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. Virus Res (2006) 0.88
Epidemiology. Emerging disease or diagnosis? Science (2012) 0.86
Serologic evidence of human orthopoxvirus infections in Sierra Leone. BMC Res Notes (2011) 0.85
Lassa virus-infected rodents in refugee camps in Guinea: a looming threat to public health in a politically unstable region. Vector Borne Zoonotic Dis (2007) 0.85
Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus. J Virol (2013) 0.85
Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone. Virol J (2010) 0.84
Interferon alpha-2b inhibits negative-strand RNA and protein expression from full-length HCV1a infectious clone. Exp Mol Pathol (2004) 0.84
Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects. Virol J (2010) 0.83
Female genital mutilation in sierra leone: forms, reliability of reported status, and accuracy of related demographic and health survey questions. Obstet Gynecol Int (2013) 0.83
Intracellular expression of IRF9 Stat fusion protein overcomes the defective Jak-Stat signaling and inhibits HCV RNA replication. Virol J (2010) 0.83
Epstein-Barr virus and human hepatocellular carcinoma. Cancer Lett (2003) 0.82
Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation. PLoS One (2013) 0.82
Seroreactivity to A-type retrovirus proteins in a subset of cats with hyperthyroidism. Microsc Res Tech (2005) 0.81
Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali. Emerg Infect Dis (2016) 0.81
Characterization of the Lassa virus GP1 ectodomain shedding: implications for improved diagnostic platforms. Virol J (2009) 0.81
Involvement of human intracisternal A-type retroviral particles in autoimmunity. Microsc Res Tech (2005) 0.81
Peptide inhibition of human cytomegalovirus infection. Virol J (2011) 0.81
Altered immune responses in rhesus macaques co-infected with SIV and Plasmodium cynomolgi: an animal model for coincident AIDS and relapsing malaria. PLoS One (2009) 0.80
Amniotic fluid has higher relative levels of lentivirus-specific antibodies than plasma and can contain neutralizing antibodies. J Clin Virol (2004) 0.80
Synergistic inhibition of SARS-coronavirus replication by type I and type II IFN. Adv Exp Med Biol (2006) 0.79
Evidence of HIV exposure and transient seroreactivity in archived HIV-negative severe hemophiliac sera. Virol J (2005) 0.79
Down-regulation of cell surface CXCR4 by HIV-1. Virol J (2008) 0.79
Alterations in intracellular potassium concentration by HIV-1 and SIV Nef. Virol J (2008) 0.78
Dengue in the Dominican Republic: epidemiology for 2004. Microsc Res Tech (2005) 0.78
A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses. PLoS Negl Trop Dis (2013) 0.78
Proteomics computational analyses suggest that the bornavirus glycoprotein is a class III viral fusion protein (gamma penetrene). Virol J (2009) 0.78
The proteasome and its implications in rheumatology. J Rheumatol (2005) 0.78
Avian dark cells. Eur Arch Otorhinolaryngol (2002) 0.77
Treatment of warts. N Engl J Med (2004) 0.77
Expression of granzyme B mRNA is altered in human immunodeficiency virus infected patients. Exp Mol Pathol (2003) 0.77
Anti-20S proteasome antibodies in psoriatic arthritis. J Rheumatol (2008) 0.77
Musculoskeletal and autoimmune manifestations of HIV, syphilis and tuberculosis. Curr Opin Rheumatol (2006) 0.77
Vaccinia virus-induced inhibition of nitric oxide production. J Surg Res (2003) 0.77
Unexpected similarity between the carboxyl termini of lentivirus and pestivirus envelope glycoproteins. AIDS (2003) 0.76
Linking chronic wasting disease to scrapie by comparison of Spiroplasma mirum ribosomal DNA sequences. Exp Mol Pathol (2004) 0.76